---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-085927"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2022-03-28T23:59:59+00:00"
generated_at: "2026-06-26T16:29:48.776254+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics reports Q4 2021 net loss $22.0M; cash $485.3M; TNG908 Fast Track

## Summary
- Net loss Q4 2021: $22.0M ($0.25/share) vs $8.9M ($0.22/share) in Q4 2020; full year $58.2M ($0.94/share).
- Revenue Q4 2021: $5.7M vs $9.1M in Q4 2020; full year $37.0M vs $7.7M in 2020 (Gilead amendment effect).
- Cash, equivalents & marketable securities: $485.3M as of Dec 31, 2021, expected to fund operations into H2 2024.
- TNG908 (PRMT5 inhibitor) granted FDA Fast Track; Phase 1/2 trial expected to start Q2 2022.
- Target 3 and USP1 development candidates expected Q2 and H2 2022, respectively; leadership team expanded.

## SEC filing metadata
- accession: 0001193125-22-085927
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2022-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312522085927/0001193125-22-085927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312522085927/d240035d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-085927
- JSON: https://secwatch.observer/filing/0001193125-22-085927.json
- Plain text: https://secwatch.observer/filing/0001193125-22-085927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.